Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/22/2018 |
| Start Date: | July 26, 2012 |
| End Date: | May 14, 2015 |
NAC is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a
common over-the-counter supplement and also is available as an injectable pharmaceutical that
protects the liver in cases of acetaminophen overdose. In the exercise physiology literature,
both oral and injectable NAC have been shown to reduce fatigue and improve recovery from
exertion which has interesting implications for exploring cancer-related fatigue.
In terms of cancer cell biology, reactive oxygen species (ROS) may play an important role in
the development and progression of breast cancer
common over-the-counter supplement and also is available as an injectable pharmaceutical that
protects the liver in cases of acetaminophen overdose. In the exercise physiology literature,
both oral and injectable NAC have been shown to reduce fatigue and improve recovery from
exertion which has interesting implications for exploring cancer-related fatigue.
In terms of cancer cell biology, reactive oxygen species (ROS) may play an important role in
the development and progression of breast cancer
Inclusion Criteria:
- Demographic • Females ≥18 years of age
Disease related
- Stage 0/I breast cancer by biopsy (patients may be consented and screened with
suspected breast cancer, but no treatment will occur until cancer is confirmed by
their biopsy).
- Awaiting surgery which will consist of either lumpectomy or mastectomy.
- ECOG performance status 0-1
Laboratory
- Laboratory values that would not prevent the patient from receiving treatment as
determined by the PI or study oncologist
- Serum creatinine ≤2.0 mg/dL
- Serum bilirubin ≤2.0 X ULN
- Serum HgB ≥8.0 mg/dL
General
- Competent to comprehend, sign, and date an IRB-approved informed consent form
- Female subjects of childbearing potential have a negative pregnancy test
Exclusion Criteria:
- Disease Related
- History or known presence of metastases
- History of another primary cancer, except:
- Curatively treated cervical carcinoma in situ, or
- Curatively resected non-melanomatous skin cancer, or
- Other primary solid tumor curatively treated with no known active disease present and
no treatment administered for ≤ 3 years prior to enrollment
- Other concurrent anticancer chemotherapy within 4 weeks as determined by the PI
- Any co-morbid disease that would increase risk of toxicity as determined by PI
Medications/Treatments
- Subjects requiring chronic use of immunosuppressive agents (eg, methotrexate,
cyclosporine, corticosteroids)
- Recent infection requiring a course of systemic anti-infectives that was completed ≤
14 days prior to enrollment (exception can be made at the judgment of the PI for oral
treatment of an uncomplicated urinary tract infection ([UTI])
General
- History of any medical or psychiatric condition or addictive disorder, or laboratory
abnormality that, in the opinion of the PI, may increase the risks associated with
study participation or study drug administration or may interfere with the conduct of
the study or interpretation of study requirements
- History of bronchospasm or severe asthma as determined by the PI
- Subject unwilling or unable to comply with study requirements
- Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus,
chronic active hepatitis B infection
- Documented history of alcohol, cocaine or intravenous drug abuse ≤ 6 months of
enrollment
We found this trial at
1
site
Click here to add this to my saved trials
